Trastuzumab achieves slight reduction in recurrence for women with HER2-positive DCIS
The addition of the monoclonal antibody therapy trastuzumab to radiotherapy did not reach the protocol objective of a 36% reduction in the ipsilateral breast tumor recurrence rate for women with HER2-positive ductal carcinoma ...
May 29, 2020
0
0